ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone201-478-5552
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.99 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableOptionable
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) released its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.02. The biotechnology company earned $4.23 million during the quarter, compared to analyst estimates of $5.39 million. ADMA Biologics had a negative net margin of 387.07% and a negative return on equity of 194.76%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
5 brokers have issued 12 month price targets for ADMA Biologics' stock. Their predictions range from $7.50 to $13.00. On average, they expect ADMA Biologics' share price to reach $10.4167 in the next twelve months. This suggests a possible upside of 214.7% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
What are Wall Street analysts saying about ADMA Biologics stock?
Here are some recent quotes from research analysts about ADMA Biologics stock:
- 1. HC Wainwright analysts commented, "We note that Perceptive Credit Holdings is an investment entity of Perceptive Life Advisors, which is one of ADMA’s largest institutional shareholders. In our view, Perceptive’s extension of credit to ADMA underscores the investor’s confidence in the company." (2/21/2019)
- 2. Maxim Group analysts commented, "ADMA announced that FDA has accepted the BLA resubmission for RI-002, the company’s specialized IVIG immunoglobulin for Primary Immune Deficiency Disease (PIDD) and assigned a PDUFA date on April 2, 2019." (10/17/2018)
Has ADMA Biologics been receiving favorable news coverage?
News coverage about ADMA stock has trended somewhat positive recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ADMA Biologics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Are investors shorting ADMA Biologics?
ADMA Biologics saw a increase in short interest in February. As of February 15th, there was short interest totalling 2,323,679 shares, an increase of 32.8% from the January 31st total of 1,750,187 shares. Based on an average daily trading volume, of 1,032,330 shares, the days-to-cover ratio is presently 2.3 days. View ADMA Biologics' Current Options Chain.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Voyager Therapeutics (VYGR), Scholar Rock (SRRK), MeiraGTx (MGTX), DBV TECHNOLOGIE/S (DBVT), PDL BioPharma (PDLI), Replimune Group (REPL), Mesoblast (MESO), Avrobio (AVRO), Translate Bio (TBIO), Adaptimmune Therapeutics (ADAP), Agenus (AGEN), Adverum Biotechnologies (ADVM), Solid Biosciences (SLDB), Krystal Biotech (KRYS) and Gritstone Oncology (GRTS).
What other stocks do shareholders of ADMA Biologics own?
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 71)
- Mr. Brian Lenz CPA, Exec. VP & CFO (Age 47)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.12%), BlackRock Inc. (2.08%), Geode Capital Management LLC (0.60%), Geode Capital Management LLC (0.60%), Diag Capital Management LP (0.39%) and Delek Group Ltd. (0.26%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Which major investors are selling ADMA Biologics stock?
Which major investors are buying ADMA Biologics stock?
ADMA stock was purchased by a variety of institutional investors in the last quarter, including Diag Capital Management LP, Delek Group Ltd., Geode Capital Management LLC, Geode Capital Management LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, United Services Automobile Association and Raymond James & Associates. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $3.31.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $153.42 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.
What is ADMA Biologics' official website?
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
